iTonic Holdings Ltd

iTonic Holdings Ltd (ITOC) Stock Analysis

$0.300

+0.008 (+2.81%)At close

Loading chart…
High
0.310
Open
0.292
VWAP
0.30
Vol
33.43K
Mkt Cap
Low
0.292
Amount
10.05K
EV/EBITDA, TTM
0.00

iTonic Holdings Ltd, formerly Pheton Holdings Ltd, is a holding company principally engaged in the provision of healthcare solutions through its subsidiary Beijing Feitian Zhaoye Technology Co., Ltd. (Beijing Feitian). The Company’s main businesses include development and commercialization of brachytherapy treatment planning system (TPS) specifically used for radioactive particle implantation, a type of radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. TPS is generally a computer software used in different types of radiotherapy. The Company’s main product is FTTPS, a user-oriented TPS for treating a wide variety of malignant tumors. Beijing Feitian’s product portfolio also includes Medical Auxiliary Supplies such as seed implant needles, computer workstations, patient positioning device and others.

AI analysis of iTonic Holdings Ltd (ITOC)

sell

iTonic Holdings Ltd is not a good buy right now due to significant risks and negative catalysts. The stock has a current price of 0.32, and it has experienced a staggering 64.90% decline year-to-date. Additionally, a class action lawsuit has been filed against the company, alleging securities fraud, which adds to the uncertainty surrounding the stock.

Valuation Metrics

The current forward P/E ratio for iTonic Holdings Ltd (ITOC) is 0.00, compared to its 5-year average forward P/E of .

Forward P/E

5Y Average P/E
Current P/E
0.00

Forward EV/EBITDA

5Y Average EV/EBITDA
Current EV/EBITDA
0.00

Forward P/S

5Y Average P/S
Current P/S
0.00

ITOC FAQ — answered by Alphio AI

iTonic Holdings Ltd, formerly Pheton Holdings Ltd, is a holding company principally engaged in the provision of healthcare solutions through its subsidiary Beijing Feitian Zhaoye Technology Co., Ltd. (Beijing Feitian). The Company’s main businesses include development and commercialization of brachytherapy treatment planning system (TPS) specifically used for radioactive particle implantation, a type of radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. TPS is generally a computer software used in different types of radiotherapy. The Company’s main product is FTTPS, a user-oriented TPS for treating a wide variety of malignant tumors. Beijing Feitian’s product portfolio also includes Medical Auxiliary Supplies such as seed implant needles, computer workstations, patient positioning device and others. It operates in the Healthcare sector.

iTonic Holdings Ltd is not a good buy right now due to significant risks and negative catalysts. The stock has a current price of 0.32, and it has experienced a staggering 64.90% decline year-to-date. Additionally, a class action lawsuit has been filed against the company, alleging securities fraud, which adds to the uncertainty surrounding the stock.

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Get Started